Takeda Earns Minnesota Governor's Safety Award

"We are very glad to be recognized for our commitment to workplace safety," said Eric Hahn, site head for Takeda's Brooklyn Park facility.  "Our state of the art biopharmaceutical manufacturing facility in Brooklyn Park is undergoing extensive construction work in order to prepare it for  production starting in 2018.  While we have a great deal of activity underway, ensuring worker safety is our top priority."      

Since acquiring the more than 200,000 square foot facility in 2015 in Brooklyn Park, Takeda is investing more than $75 million in modifications and upgrades.  The company estimates that more than 1,000,000 man hours will be dedicated to construction, project management and other activities to ready the plant for full production. 

Takeda has added more than 120 positions in Brooklyn Park since the acquisition in 2015 and plans to hire approximately 80 additional positions over the next two years.  When the facility is fully operational in 2019, it will be Takeda's first U.S. based manufacturing facility, joining the company's global network of 23 manufacturing sites around the world. 

The company initially plans to manufacture Entyvio at the facility, a product used in the treatment of ulcerative colitis and Crohn's disease. 

"We thank Takeda Pharmaceuticals for its commitment to safety," said Paul Aasen, president of the Minnesota Safety Council. "These efforts protect workers, strengthen the organization and benefit the community as a whole."

Since 1934, the annual Governor's Safety Awards program has honored Minnesota employers with exceptional safety performance. Applicants are judged on several years of injury data as it compares with their industry's national statistics, and on their progress in implementing a comprehensive safety program.

The Governor's Safety Awards luncheon is part of the 83^rd Minnesota Safety & Health Conference, coordinated by the Minnesota Safety Council. The conference is the oldest and largest gathering of workplace safety and health professionals in the region. The Minnesota Safety Council, founded in 1928, is a non-governmental, not-for-profit organization dedicated to improving the quality of life in Minnesota by preventing unintentional injuries ("accidents").

This award from the Minnesota Safety Council joins a long list of workplace awards Takeda has earned based on its employee policies and programs.  Takeda was included for the fourth year in the Working Mother 100 Best Companies 2016 list and was recognized by Forbes as one of the best mid-size biotech employers in 2016 and 2017.

About Takeda

Takeda Pharmaceutical Company Limited is a global, R&D-driven pharmaceutical company committed to bringing better health and a brighter future to patients by translating science into life-changing medicines. Takeda focuses its research efforts on oncology, gastroenterology and central nervous system therapeutic areas. It also has specific development programs in specialty cardiovascular diseases as well as late-stage candidates for vaccines. Takeda conducts R&D both internally and with partners to stay at the leading edge of innovation. New innovative products, especially in oncology and gastroenterology, as well as its presence in emerging markets, fuel the growth of Takeda. More than 30,000 Takeda employees are committed to improving quality of life for patients, working with our partners in health care in more than 70 countries.

Additional information about Takeda is available through its corporate website, www.takeda.com. 

SOURCE Takeda Pharmaceuticals

Related Links

http://www.takeda.com